Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 6 of 6 for “"AICART"”.

  1. ANTIFOLATE MODULATORS OF AMP-ACTIVATED PROTEIN KINASE SIGNALING AS CANCER THERAPEUTICS

    … ribonucleotide formyltransferase (AICART), the second folate- dependent enzyme of de novo purine synthesis. Consequent of AICART inhibition, pemetrexed caused robust activation of a key energy-sensing regulatory enzyme of the PI3K-AKT signal transduction pathway, AMP-activated …

    vcu Repository record for ANTIFOLATE MODULATORS OF AMP-ACTIVATED PROTEIN KINASE SIGNALING AS CANCER THERAPEUTICS (opens in a new tab)

  2. THERAPEUTIC EFFICACY OF COMBINATION OF MTOR INHIBITORS AND AMPK ACTIVATORS IN NON-SMALL CELL LUNG CANCER.

    … ribonucleotide formyltransferase (AICART). The accumulation of the substrate for AICART, ZMP, in PTX-inhibited cancer cells leads to activation of AMP-activated protein kinase (AMPK) with subsequent inhibition of mammalian target of rapamycin (mTOR) and hypophosphorylation of its …

    vcu Repository record for THERAPEUTIC EFFICACY OF COMBINATION OF MTOR INHIBITORS AND AMPK ACTIVATORS IN NON-SMALL CELL LUNG CANCER. (opens in a new tab)

  3. TRANSCRIPTIONAL, EPIGENETIC, AND SIGNAL EVENTS IN ANTIFOLATE THERAPEUTICS

    … steps of purine synthesis (GART or AICART) activate AMP-dependent protein kinase (AMPK) and inhibit mTOR. The mechanism of AMPK stimulation appears to be mediated by either nucleotide depletion (GART inhibitors), or ZMP accumulation (AICART inhibitors). These studies discovered a new …

    vcu Repository record for TRANSCRIPTIONAL, EPIGENETIC, AND SIGNAL EVENTS IN ANTIFOLATE THERAPEUTICS (opens in a new tab)

  4. RHEB DYNAMICS ON LYSOSOMAL MEMBRANES DETERMINES MTORC1 ACTIVITY AFTER LOSS OF P53 OR ACTIVATION OF AMPK

    … activate AMPK via the inhibition of the enzyme AICART in de novo purine synthesis. This work presents a mechanism of mTORC1 activation with p53 loss, as well as of mTORC1 inhibition by pemetrexed-induced AMPK. We have found that mTORC1 activity was substantially upregulated by the loss or …

    vcu Repository record for RHEB DYNAMICS ON LYSOSOMAL MEMBRANES DETERMINES MTORC1 ACTIVITY AFTER LOSS OF P53 OR ACTIVATION OF AMPK (opens in a new tab)

  5. Sorafenib enhances pemetrexed-induced cytotoxicity through and autophagy-dependent mechanism in cancer cells

    … ribonucleotide formyltransferase (AICART); both important for DNA synthesis. Studies performed by our collaborator demonstrated that TS inhibition causes intracellular accumulation of ZMP+ and activation of AMPK which is known to induce autophagy in mammalian cells. Previous studies …

    vcu Repository record for Sorafenib enhances pemetrexed-induced cytotoxicity through and autophagy-dependent mechanism in cancer cells (opens in a new tab)

  6. Pemetrexed, A Modulator of AMP-activated Kinase Signaling and an Inhibitor of Wild type and Mutant p53

    … ribonucleotide formyltransferase (AICART), the second folate-dependent enzyme of de novo purine synthesis. Inhibition of AICART leads to massive accumulation of its substrate 5-amino-4-imidazolecarboxamide ribonucleotide (ZMP), causing activation of AMP-dependent kinase (AMPK), …

    vcu Repository record for Pemetrexed, A Modulator of AMP-activated Kinase Signaling and an Inhibitor of Wild type and Mutant p53 (opens in a new tab)